Conditions: Cancer; Solid Tumor; Melanoma; Carcinoma; Sarcoma; Lung Cancer; Prostate Cancer; Breast Cancer; Colo-rectal Cancer; Uterine Cancer; Pancreatic Cancer; Gastric Cancer; Esophageal Cancer; Thyroid Cancer; Ovarian Cancer; Kidney Cancer; Head and Neck Cancer
Interventions: Drug: KVA12123 – Dose Escalation; Drug: KVA12123 Plus Pembrolizumab – Dose Escalation; Drug: KVA12123 – Dose Expansion; Drug: KVA12123 Plus Pembrolizumab – Dose Expansion
Sponsors: Kineta Inc.; Merck Sharp & Dohme LLC
Completed
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
